Posted on 09/13/2021 9:17:35 PM PDT by SeekAndFind
Probenecid, an FDA-approved gout treatment with “powerful antiviral properties” and minimal side effects, is “a prime candidate” for treating COVID-19 according to a new study.
SciTechDaily reports on recent research from the University of Georgia, where they found that probenecid “works as a prophylactic prior to virus exposure and as a post-exposure treatment in animal models against SARS-CoV-2 and flu.”
Ralph Tripp, lead author of the study, concluded, “This antiviral works for all RNA respiratory viruses we tested, including SARS-CoV-2. RSV, coronavirus and flu all circulate in the same season. Bottom line is you can potentially reduce infection and disease using this one oral drug.”
This is potentially great news.
COVID-19 hospitalizations have gone up in recent weeks as the delta variant makes its way through the population. Even though delta is far less deadly than the initial version of the Wuhan Flu, nobody wants to end up stuck in a hospital or on a ventilator.
Tripp’s company, TrippBio, is set to begin clinical trials of probenecid against COVID later this year.
Recommended: Biden White House Knows the Vaccine Mandate Is Illegal. Here’s Proof.
Although I do wish they’d hurry it up.
Floridians and Texans have already gotten through the worst of the delta spike, but seasonality means it’s heading north for the winter.
The wave is about to increase up north. It's decreasing in the south.
As winter and indoors comes for the north, so will COVID.
As summer and A/C leaves the south, so will COVID.
Lesson: Keep your windows open.
Also, your moral preening does not affect COVID.
— Melissa Mackenzie (@MelissaTweets) September 10, 2021
(Excerpt) Read more at pjmedia.com ...
[EXCERPT]
Viruses work by coopting a person’s own cells to replicate and produce more of the virus. Probenecid blocks that replication process, keeping the virus from infecting the individual’s cells.
In clinical development at the pharmaceutical company TrippBio, Tripp showed the drug, Probenecid works as a prophylactic prior to virus exposure and as a post-exposure treatment in animal models against SARS-CoV-2 and flu. The drug also has proven effective in fighting the RSV in vitro, and in vivo studies are in progress.
Although the drug would primarily be used after a person is positive for the virus, the prophylactic findings mean people with known exposures could also potentially take the drug to prevent getting sick.
The current go-to treatments for seriously ill COVID-19 patients, remdesivir and monoclonal antibodies, can only be given through an IV. And by the time a COVID patient needs them, it’s often too late.
“These treatments have seen some effectiveness against SARS-CoV-2, but they’re very expensive and very hard to come by,” Tripp said. “In reality, there are only a handful of options that can actually be used because of the cost, restricted IV usage, and lack of access. That’s not very useful to the world.”
Probenecid, on the other hand, is widely available. Primary care physicians could prescribe a pill to patients, and they could pick it up at their local drugstore.
Repurposing drugs that are already approved to work against one problem is common. For example, remdesivir was originally intended to fight Ebola virus, but when it showed some promise in fighting the coronavirus, it was enlisted to battle COVID-19.
In addition to preventing illness before it starts, probenecid may also potentially increase the efficacy of other treatments. Probenecid is already used to up the potency of some antibiotics, so it’s possible the medication could work in conjunction with other COVID-19 treatments as well.
As stated........“This antiviral works for ALL RNA respiratory viruses we tested, including SARS-CoV-2. RSV, coronavirus and flu... all circulate in the same season. Bottom line is you can potentially reduce infection and disease using this one oral drug.”
Well let’s just see about that.
’ Probenecid ‘...blocks that replication process, keeping the virus from infecting the individual’s cells.
Very interesting!
Bookmark
Promising news.
But like with HCQ, our gubmint thugs won’t allow its use because they won’t make any money from it.
1. Ignore the data that it works.
2. Do not allow research funding for prevention and early treatment.
3. Run a few studies for patients that are already hospitalized where it most likely will not work.
4. Issue a statement that is it not recommended and may be dangerous.
5. Get on the news saying "the science isn't there for it" for a week.
Even more then the money, they cannot control us if they give us something that works against the virus.
Self ping
That too. A combination of the two.
I am kinda noticing a pattern.
6. This is too long to read.
(I read 1-5 in faucis voice)
Seems like the same would be true for many other ailments.
Money doesn’t seem to be much of a priority for them now. They might have needed it in the beginning to get things going. but now they already invested it all in the end game.
Resembles Steve Irwin.
I’ll have to text this to my vet to see if he knows this guy. They look to be around the same age, and my vet is a UGA guy.
Chemosensitization of Plasmodium falciparum by probenecid in vitro
You see what they're doing?
Anything that's not called Ivermectin.
Bkmk
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.